A Phase 3 interventional study of Empagliflozin and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 24 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-15.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 34th largest by enrollment, is one of 13 that started in 2020, is one of 28 in phase 3, and was the 76th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Celltrion · Sites in Korea, Republic of
Ages 19+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 13 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 79 across the 130 interventional studies. Of the 91 that completed or were terminated, 38 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 130 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 60th largest by enrollment of the 96 interventional ones that give a count, is one of 5 that started in 2020, is one of 50 in phase 3, and was the 118th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
10 of the studies testing empagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT05960656The University of Texas Health Science Center at San AntonioSGLTi, Hepatic Glucose Production and Ketogenesis | 2027-06-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes. The purpose of this study is to find out whether empagliflozin taken together with insulin helps people with type 2 diabetes to better control their blood sugar.
The participants are in the study for about 7 months. During this time, they visit the study site about 8 times, 1 additional visit may be either a visit to the study site or a phone call. At the start of the study, participants are put into 3 groups by chance. Participants get either 10 mg empagliflozin tablets, or 25 mg empagliflozin tablets, or placebo tablets once a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine.
The doctors regularly take blood samples from the participants. The changes in blood sugar levels are compared between the groups. The doctors also check the general health of the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A stable treatment with premixed Insulin (≥ 20IU/day) or basal insulin (≥ 16 IU/day) for at least 12 weeks prior to enrolment with or without up to two OADs
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 table of 10 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks. Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily.
Drug: Empagliflozin
1 table of 25 milligrams (mg) of Empagliflozin was administered orally once daily for a treatment period of 24 weeks. Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily.
Drug: Empagliflozin
Matching placebo was administered orally once daily for a treatment period of 24 weeks. Before the first dose of randomised drug, all participants went through a 2-week open label placebo run-in period, taking Placebo tablets orally once daily.
Drug: Placebo
Empagliflozin
Placebo
Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24
A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including treatment, background therapy, and visit as fixed classification effects, baseline HbA1c and baseline estimated glomerular filtration rate (eGFR) as the linear covariates, treatment by visit interaction, and baseline HbA1c by visit interaction.
Time frame: At baseline (Week 0) and at Week 24
Percentage of Participants With HbA1c<7.0% at Week 24
Percentage of participants with glycosylated haemoglobin A1c (HbA1c) \<7.0% at Week 24 is reported.
Time frame: At Week 24
Change in Body Weight From Baseline to Week 24
Change in body weight from baseline to Week 24 is reported. A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline body weight, and its interaction with visit.
Time frame: At baseline (Week 0) and at Week 24
Change From Baseline in Systolic Blood Pressure (SBP) at Week 24
A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline SBP and its interaction with visit.
Time frame: At baseline (Week 0) and at Week 24
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 24
A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline DBP and its interaction with visit.
Time frame: At baseline (Week 0) and at Week 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline FPG and its interaction with visit.
Time frame: At baseline (Week 0) and at Week 24
Change From Baseline in 2-hour Post-prandial Glucose (PPG) at Week 24
The Analysis of covariance (ANCOVA) model included treatment and background therapy as classification effects, baseline PPG and baseline Estimated glomerular filtration rate (eGFR) as the linear covariates.
Time frame: At baseline (Week 0) and at Week 24
Number of Participants With Confirmed Hypoglycaemic Events
Confirmed hypoglycemic events refer to the hypoglycaemic events with a plasma glucose value of ≤70 milligrams per deciliter (mg/dL) or where assistance was required.
Time frame: From first administration of the initial randomised study medication to last intake of study medication + 7 days (inclusive), up to 176 days.
Number of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events
The risk of DKA had to be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty in breathing, confusion, unusual fatigue or sleepiness. In case of a suspected DKA, the investigator was to ensure that appropriate tests were performed at the earliest opportunity according to 2017 China Type 2 diabetes mellitus (T2DM) guidelines. An independent external Clinical event committee (CEC) was established to adjudicate centrally and in a blinded fashion events suspected of DKA and certain hepatic events. DKA was investigated using both broad and narrow Boehringer Ingelheim customised MedDRA query (BIcMQs).
Time frame: From first administration of the initial randomised study medication to last intake of study medication + 7 days (inclusive), up to 176 days.
This study was to determine the efficacy and safety of Empagliflozin added to insulin-treated type 2 diabetes patients.
| Milestone | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Started | 73 | 73 | 73 |
| Completed | 73 | 71 | 69 |
| Not completed | 0 | 2 | 4 |
| Withdrew: Other than listed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 3 |
A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including treatment, background therapy, and visit as fixed classification effects, baseline HbA1c and baseline estimated glomerular filtration rate (eGFR) as the linear covariates, treatment by visit interaction, and baseline HbA1c by visit interaction.
| Percentage of glycosylated hemoglobin | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24 | -0.13 ± 0.10 | -1.12 ± 0.10 | -1.12 ± 0.10 |
Percentage of participants with glycosylated haemoglobin A1c (HbA1c) \<7.0% at Week 24 is reported.
| Percentage of participants | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Percentage of Participants With HbA1c<7.0% at Week 24 | 8.2 | 16.7 | 30.1 |
Change in body weight from baseline to Week 24 is reported. A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline body weight, and its interaction with visit.
| Kilogram | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change in Body Weight From Baseline to Week 24 | 0.01 ± 0.23 | -1.99 ± 0.24 | -1.31 ± 0.24 |
A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline SBP and its interaction with visit.
| Millimetre of mercury (mmHg) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) at Week 24 | -1.95 ± 1.38 | -5.56 ± 1.49 | -2.96 ± 1.46 |
A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline DBP and its interaction with visit.
| Millimetre of mercury (mmHg) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) at Week 24 | -1.59 ± 0.78 | -3.37 ± 0.84 | -0.94 ± 0.83 |
A restricted maximum likelihood (REML) based mixed model repeated measures (MMRM) approach was applied including baseline FPG and its interaction with visit.
| Milligrams per deciliter (mg/dL) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | -5.56 ± 3.67 | -25.61 ± 3.97 | -29.69 ± 3.90 |
The Analysis of covariance (ANCOVA) model included treatment and background therapy as classification effects, baseline PPG and baseline Estimated glomerular filtration rate (eGFR) as the linear covariates.
| Milligrams per deciliter (mg/dL) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Change From Baseline in 2-hour Post-prandial Glucose (PPG) at Week 24 | 3.27 ± 7.53 | -53.05 ± 8.14 | -57.44 ± 7.89 |
Confirmed hypoglycemic events refer to the hypoglycaemic events with a plasma glucose value of ≤70 milligrams per deciliter (mg/dL) or where assistance was required.
| Participants | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Number of Participants With Confirmed Hypoglycaemic Events | 8 | 13 | 7 |
The risk of DKA had to be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty in breathing, confusion, unusual fatigue or sleepiness. In case of a suspected DKA, the investigator was to ensure that appropriate tests were performed at the earliest opportunity according to 2017 China Type 2 diabetes mellitus (T2DM) guidelines. An independent external Clinical event committee (CEC) was established to adjudicate centrally and in a blinded fashion events suspected of DKA and certain hepatic events. DKA was investigated using both broad and narrow Boehringer Ingelheim customised MedDRA query (BIcMQs).
| Participants | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|
| Number of Participants With Adjudicated Diabetic Ketoacidosis (DKA) Events | 0 | 0 | 0 |
Collected over For Run-in period group: from first dose of open label placebo till end of run-in period, up to 2 weeks. For the other groups: From first administration of the initial randomised study medication to last intake of study medication + 7 days (inclusive), up to 176 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/73 (0%) | 6/73 (8.2%) | 39/73 (53.4%) |
| Empagliflozin 10 mg | 0/73 (0%) | 10/73 (13.7%) | 27/73 (37%) |
| Empagliflozin 25 mg | 0/73 (0%) | 7/73 (9.6%) | 27/73 (37%) |
| Run-in Period | 0/219 (0%) | 2/219 (0.9%) | 46/219 (21%) |
| Event | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg | Run-in Period |
|---|---|---|---|---|
| Angina unstableCardiac disorders | 0/73 | 0/73 | 1/73 | 0/219 |
| ArrhythmiaCardiac disorders | 0/73 | 1/73 | 0/73 | 0/219 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/73 | 1/73 | 1/73 | 0/219 |
| Deafness neurosensoryEar and labyrinth disorders | 1/73 | 0/73 | 0/73 | 0/219 |
| HyperparathyroidismEndocrine disorders | 0/73 | 1/73 | 0/73 | 0/219 |
| Thyroid massEndocrine disorders | 0/73 | 1/73 | 0/73 | 0/219 |
| CataractEye disorders | 0/73 | 0/73 | 1/73 | 0/219 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 0/73 | 1/73 | 0/73 | 0/219 |
| Cholecystitis chronicHepatobiliary disorders | 0/73 | 1/73 | 0/73 | 0/219 |
| CholelithiasisHepatobiliary disorders | 0/73 | 1/73 | 0/73 | 0/219 |
| Event | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg | Run-in Period |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 11/73 | 15/73 | 11/73 | 9/219 |
| Urinary tract infectionInfections and infestations | 10/73 | 6/73 | 6/73 | 10/219 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/73 | 0/73 | 3/73 | 0/219 |
| Diabetic nephropathyRenal and urinary disorders | 6/73 | 0/73 | 1/73 | 11/219 |
| Upper respiratory tract infectionInfections and infestations | 5/73 | 4/73 | 4/73 | 3/219 |
| Electrocardiogram T wave abnormalInvestigations | 5/73 | 1/73 | 2/73 | 0/219 |
| Protein urine presentInvestigations | 4/73 | 2/73 | 3/73 | 15/219 |
| HyperlipidaemiaMetabolism and nutrition disorders | 2/73 | 4/73 | 4/73 | 1/219 |
Treated set (TS): The TS consisted of all patients who were randomised and treated with at least one dose of the study drug. The assignment of patients to treatment groups were based on the actual first study drug intake in the double-blind treatment period.
| Age, Continuous(Years) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| Mean | 60.1 ± 8.0 | 59.9 ± 7.7 | 60.7 ± 9.1 | 60.2 ± 8.2 |
| Sex: Female, Male(Participants) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| Female | 37 | 30 | 33 | 100 |
| Male | 36 | 43 | 40 | 119 |
| Race (NIH/OMB)(Participants) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 73 | 73 | 73 | 219 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Glycosylated haemoglobin A1c (HbA1c)(Percentage of glycosylated hemoglobin) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| Mean | 8.64 ± 0.81 | 8.64 ± 0.91 | 8.64 ± 0.88 | 8.64 ± 0.87 |
| Time since diagnosis of diabetes(Years) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| Mean | 14.14 ± 7.26 | 14.74 ± 7.01 | 15.05 ± 7.45 | 14.64 ± 7.22 |
| Background antidiabetic treatment(Participants) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| Insulin + Oral antidiabetic drug (OAD) | 60 | 59 | 59 | 178 |
| Insulin only | 13 | 14 | 14 | 41 |
| Type of insulin(Participants) | Placebo | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|
| Basal | 32 | 38 | 34 | 104 |
| Pre-mixed | 41 | 35 | 39 | 115 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Apr 2020 to primary completion in Mar 2022, 22 months.
Results were first posted in Dec 2023, 1 year 9 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin